Marcus Pickhardt

Ludwig Erhard Allee 2
Bonn, NW 53175, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Screening of a neuronal cell model of tau pathology for therapeutic compounds.

Screening of a neuronal cell model of tau pathology for therapeutic compounds.

Journal: Neurobiology of aging

Published: September 19, 2018

Structural Basis of Small Molecule Targetability of Monomeric Tau Protein.

Structural Basis of Small Molecule Targetability of Monomeric Tau Protein.

Journal: ACS chemical neuroscience

Published: June 27, 2018

On the way to precision formulation additives: 2D-screening to select solubilizers with tailored host and release capabilities.

On the way to precision formulation additives: 2D-screening to select solubilizers with tailored host and release capabilities.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 28, 2018

Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Anti-Alzheimer Disease Drug B4A1.

Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Anti-Alzheimer Disease Drug B4A1.

Journal: Macromolecular bioscience

Published: March 21, 2017

Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy.

Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy.

Journal: Neurobiology of aging

Published: December 18, 2016

Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.

Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.

Journal: PloS one

Published: July 08, 2016

Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability.

Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability.

Journal: Current Alzheimer research

Published: May 16, 2016

Generalizing the Concept of Specific Compound Formulation Additives towards Non-Fluorescent Drugs: A Solubilization Study on Potential Anti-Alzheimer-Active Small-Molecule Compounds.

Generalizing the Concept of Specific Compound Formulation Additives towards Non-Fluorescent Drugs: A Solubilization Study on Potential Anti-Alzheimer-Active Small-Molecule Compounds.

Journal: Angewandte Chemie (International ed. in English)

Published: February 01, 2016

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.

Journal: Acta neuropathologica communications

Published: April 15, 2015

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.

Journal: Current Alzheimer research

Published: February 20, 2015

Progress and developments in tau aggregation inhibitors for Alzheimer disease.

Progress and developments in tau aggregation inhibitors for Alzheimer disease.

Journal: Journal of medicinal chemistry

Published: March 15, 2013

Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.

Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.

Journal: Angewandte Chemie (International ed. in English)

Published: October 15, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026